GlobeNewswire

iPass Mobile Security Report: Half of Organizations Suspect Their Mobile Workers Have Been Hacked in the Last 12 Months

Dela

Cafes see highest number of Wi-Fi related incidents

 

REDWOOD SHORES, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- iPass Inc. (NASDAQ:IPAS), a leading provider of global mobile connectivity, today published the iPass Mobile Security Report 2018, revealing that more than half (57%) of organizations suspect their mobile workers have been hacked, or caused a mobile security issue, in the last 12 months. Overall, 81% of respondents said they had seen Wi-Fi related security incidents in the last 12 months, with cafes and coffee shops (62%) ranked as the venues where such incidents had occurred most. That was closely followed by airports (60%) and hotels (52%), with other locations on the list including train stations (30%), exhibition centers (26%), and in-flight (20%).

Compiling the responses of 500 organizations from the U.S., U.K., Germany and France, the annual iPass Mobile Security Report* provides an overview of how companies are dealing with the trade-off between security and the need to enable a mobile workforce. Many organizations have now implemented Bring Your Own Device (BYOD) policies to empower their mobile workers. However, for all the positives this can bring, 94% of enterprises said BYOD has increased mobile security risks. Overall, 92% of organizations said they were concerned their growing mobile workforce presents an increasing number of mobile security challenges.

"There is no escaping the fact that mobile security threats are rising. So while it is great that mobile workers are increasingly able to work from locations such as cafes, hotels and airports, there is no guarantee the Wi-Fi hotspot they are using is fully secure," said Raghu Konka, vice president of engineering at iPass. "Given the amount of high-profile security breaches in recent years, it's not surprising this issue is on the radar of CIOs. The conundrum remains: how can they keep their mobile workers secure while providing them with the flexibility to get connected anywhere using their device of choice?"

The research shows the majority of organizations are still addressing mobile security problems by banning employee usage of free Wi-Fi hotspots. More than a quarter (27%) take the hardline approach of banning their use at all times, while 40% ban their use sometimes. A further 16% plan to introduce a ban on public Wi-Fi hotspots in the future.

Many organizations use virtual private networks (VPN) to provide secure remote access to their data and systems, and the research shows that employee usage of VPNs is slowly increasing. In 2016, the iPass Mobile Security Report revealed that 26% of organizations were fully confident their mobile workers were using a VPN every time they went online, but that figure has jumped to 46% in 2018. However, that still leaves more than half (54%) of respondents reporting they still aren't fully confident their mobile workers use a VPN every time they go online.

Highlights from the report, categorized by geographic region, include:

  • CIOs from Germany (71%) are the most suspicious that their mobile workers have been hacked or caused a security issue.
  • U.K. enterprises are likely to be the most wary of employees working from cafes/coffee shops, as (81%) have seen Wi-Fi related security incidents occur in such a location. Meanwhile, alarm bells could ring for enterprises from the U.S. when their employees come online in airports, as 68% have seen an incident occur there.
  • In the U.K., almost half (42%) of enterprises have no plans to ban the use of free Wi-Fi hotspots. This is significantly higher compared to the U.S. (9%), Germany (10%), and France (12%).
  • U.K. organizations (38%) were least confident that their mobile workers are using a VPN every time they go online. The figure is higher in Germany (53%), U.S. (49%) and France (41%).

"While putting a blanket ban on accessing public Wi-Fi hotspots could initially appear to stop the security problem at the source, the fact of the matter is that mobile workers will stop at nothing to get themselves online. There's no point in putting roadblocks in their way without also providing a solution," added Konka. "Organizations must focus on taking positive action to resolve the security problems mobile workers are bringing to the table. With a secure connection through a VPN, enterprises can have confidence that Wi-Fi hotspot usage will have a positive rather than negative impact on their business. The key for organizations is to educate mobile workers about today's security threats, and to provide them with the tools to remain productive and secure."

*The research was carried out by independent market research company Vanson Bourne during February and March 2018. The sample comprised 500 CIO and IT decision makers from the U.S. (200), U.K. (100), Germany (100) and France (100).

About iPass Inc.

iPass (NASDAQ:IPAS) is a leading provider of global mobile connectivity, offering simple, secure, always-on Wi-Fi access on any mobile device. Built on a software-as-a-service (SaaS) platform, the iPass cloud-based service keeps its customers connected by providing unlimited Wi-Fi connectivity on unlimited devices. iPass is the world's largest Wi-Fi network, with more than 64 million hotspots around the globe, at airports, hotels, train stations, convention centers, outdoor venues, inflight, and more. Using patented technology, the iPass SmartConnect(TM) platform takes the guesswork out of Wi-Fi, automatically connecting customers to the best hotspot for their needs. Customers simply download the iPass SmartConnect app to experience unlimited, everywhere, and invisible Wi-Fi.

iPass® is a registered trademark of iPass Inc. Wi-Fi® is a registered trademark of the Wi-Fi Alliance. All other trademarks are owned by their respective owners.

iPass Media Contact
Spark Communications
Alex Crawshaw
Tel: +44 (0) 20 7436 0420
Email: ipass@sparkcomms.co.uk 

iPass IR Contacts
Kirsten Chapman / Becky Herrick
LHA Investor Relations
Tel: +1-415-433-3777
Email: ipass@lhai.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: iPass, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum